ACM
UTHR icon

Ascendant Capital Management’s United Therapeutics UTHR Stock Holding History

Ascendant Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,000
Closed -$556K – 80
2022
Q4 		$556K Buy
+2,000
New +$505K 1.66% 27

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ascendant Capital Management's UTHR Position: Q1 2023 in Review

Ascendant Capital Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 2,000 shares — an estimated $556K sold.

Ascendant Capital Management first reported a position in UTHR in Q4 2022 and held it in 1 quarter. The position peaked at $556K in Q4 2022. 506 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Ascendant Capital Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ascendant Capital Management sold 2,000 United Therapeutics shares in Q1 2023, an estimated $556K.
  • Ascendant Capital Management first reported a position in United Therapeutics in Q4 2022 and held it in 1 quarter.
  • Ascendant Capital Management's United Therapeutics position peaked at $556K in Q4 2022.
  • 506 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Ascendant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.